Institutional investments
SELLAS Life Sciences Group Exercises Warrants for $31 Million in Gross Cash Proceeds
SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, has announced the immediate exercise of warrants to purchase up to 22,363,714 shares of its common stock. This move is expected to bring in approximately $31.0 million in gross cash proceeds. The company has also announced the issuance